title: Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
abstract: OBJECTIVE
  We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo.
  
  
  METHODS
  In a randomized, double-blind, multicenter study, patients received ozenoxacin cream or placebo cream twice daily for 5 days (a third group received retapamulin 1% ointment as a control). Clinical, microbiological and laboratory evaluations were performed during follow-up (over 2 weeks).
  
  
  RESULTS
  Ozenoxacin was superior to placebo (success rate 34.8 vs 19.2%; p = 0.003). Microbiological success was 70.8% for ozenoxacin and 38.2% for placebo after 3-4 days and 79.2% versus 56.6% after 6-7 days. Ozenoxacin produced more rapid microbiological clearance than retapamulin. All treatments were well tolerated.
  
  
  CONCLUSIONS
  Ozenoxacin 1% cream was effective and safe in the treatment of impetigo.
authors.affiliation: Ferrer Internacional SA, Barcelona, Spain.
authors.forename: Savion
authors.initials: S
authors.lastname: Gropper
authors.forename: Nuria
authors.initials: N
authors.lastname: Albareda
authors.forename: Klaus
authors.initials: K
authors.lastname: Chelius
authors.forename: Dawie
authors.initials: D
authors.lastname: Kruger
authors.forename: Ismail
authors.initials: I
authors.lastname: Mitha
authors.forename: Yacoob
authors.initials: Y
authors.lastname: Vahed
authors.forename: Mashra
authors.initials: M
authors.lastname: Gani
authors.forename: Fernando
authors.initials: F
authors.lastname: García-Alonso
mesh_terms: D000293:Adolescent; D000631:Aminopyridines / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007169:Impetigo / Q000188:drug therapy*; D008297:Male; D009824:Ointments; D015363:Quinolones / Q000627:therapeutic use*
chemical_list: D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D009824:Ointments; D015363:Quinolones; C508887:retapamulin; C000592413:ozenoxacin
keywords: Staphylococcus aureus; Streptococcus pyogenes; impetigo; ozenoxacin; retapamulin; skin infection